<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FUROSEMIDE <img border="0" src="../images/pr.gif"/></span><br/>(fur-oh'se-mide)<br/><span class="topboxtradename">Fumide <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Furomide <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Lasix, </span><span class="topboxtradename">Luramide <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">electrolytic and water balance agent</span>; <span class="classification">loop diuretic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg, 40 mg, 80 mg tablets; 10 mg/mL, 40 mg/5 mL oral solution; 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Rapid-acting potent sulfonamide "loop" diuretic and antihypertensive with pharmacologic effects and uses almost identical
         to those of ethacrynic acid. Exact mode of action not clearly defined; decreases renal vascular resistance and may increase
         renal blood flow.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits reabsorption of sodium and chloride primarily in loop of Henle and also in proximal and distal renal tubules; an
         antihypertensive that decreases edema and intravascular volume. Reportedly less ototoxic than ethacrynic acid.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of edema associated with CHF, cirrhosis of liver, and kidney disease, including nephrotic syndrome. May be used
         for management of hypertension, alone or in combination with other antihypertensive agents, and for treatment of hypercalcemia.
         Has been used concomitantly with mannitol for treatment of severe cerebral edema, particularly in meningitis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to furosemide or sulfonamides; increasing oliguria, anuria, fluid and electrolyte depletion states;
         hepatic coma; pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Infants, older adults; hepatic cirrhosis, nephrotic syndrome; cardiogenic shock associated with acute MI; history of SLE,
         history of gout; patients receiving digitalis glycosides or potassium-depleting steroids.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Edema</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2080 mg in 1 or more divided doses up to 600 mg/d if needed <span class="rdroute">IV/IM</span> 2040 mg in 1 or more divided doses up to 600 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 2 mg/kg, may be increased by 12 mg/kg q68h (max: 6 mg/kg/dose) <span class="rdroute">IV/IM</span> 1 mg/kg, may be increased by 1 mg/kg q2h if needed (max: mg/kg/dose)<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO</span> 14 mg/kg q1224h <span class="rdroute">IV/IM</span> 12 mg/kg q1224h<br/><br/><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1040 mg b.i.d. (max: 480 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or milk to reduce possibility of gastric irritation.</li>
<li>Schedule doses to avoid sleep disturbance (e.g., a single dose is generally given in the morning; twice-a-day doses at 8 a.m.
            and 2 p.m.).
         </li>
<li> 				Note: Slight discoloration of tablets reportedly does not alter potency. 			</li>
<li>Store tablets at controlled room temperature, preferably at 15°30° C (59°86° F) unless otherwise
            directed. Protect from light.
         </li>
<li>Store oral solution in refrigerator, preferably at 2°8° C (36°46° F). Protect from light and
            freezing.
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Protect syringes from light once they are removed from package.</li>
<li>Discard yellow or otherwise discolored injection solutions.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li> 					Note: Verify correct IV concentration and rate of infusion/injection with physician before administration to infants or children. 				</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Give undiluted at a rate of 20 mg or a fraction thereof over 1 min. With high doses a rate of 4 mg/min is recommended to decrease
                  risk of ototoxicity.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Buprenorphine,</b> <b>chlorpromazine,</b> <b>ciprofloxacin,</b> <b>diazepam,</b> <b>diphenhydramine,</b> <b>dobutamine,</b> <b>doxapram,</b> <b>doxorubicin,</b> <b>droperidol,</b> <b>erythromycin,</b> <b>gentamicin,</b> <b>isoproterenol,</b> <b>labetalol,</b> <b>meperidine,</b> <b>metoclopramide,</b> <b>milrinone,</b> <b>netilmicin,</b> <b>pancuronium,</b> <b>prochlorperazine,</b> <b>promethazine,</b> <b>quinidine,</b> <b>thiamine vinblastine,</b> <b>vincristine.</b> <span class="incompattype">Y-site:</span> <b>Amrinone,</b> <b>amsacrine,</b> <b>azithromycin, ciprofloxacin,</b> <b>diazepam,</b> <b>diltiazem,</b> <b>dobutamine,</b> <b>diphenhydramine,</b> <b>dopamine,</b> <b>doxorubicin,</b> <b>droperidol,</b> <b>esmolol,</b> <b>filgrastim,</b> <b>fluconazole,</b> <b>gemcitabine,</b> <b>gentamicin,</b> <b>hydralazine,</b> <b>idarubicin,</b> <b>methocarbamol,</b> <b>metoclopramide,</b> <b>midazolam,</b> <b>milrinone,</b> <b>morphine,</b> <b>netilmicin,</b> <b>nicardipine,</b> <b>ondansetron,</b> <b>quinidine,</b> <b>thiopental,</b> <b>tobramycin,</b> <b>vecuronium,</b> <b>vinblastine,</b> <b>vincristine,</b> <b>vinorelbine,</b> TPN. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Use infusion solutions within 24 h.</li>
<li>Store parenteral solution at controlled room temperature, preferably at 15°30° C (59°86° F)
            unless otherwise directed. Protect from light.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Postural hypotension, dizziness with excessive diuresis, acute hypotensive episodes, <span class="speceff-life">circulatory collapse</span>. <span class="typehead">Metabolic:</span> Hypovolemia, dehydration, hyponatremia <span class="speceff-common">hypokalemia,</span> hypochloremia metabolic alkalosis, hypomagnesemia, hypocalcemia (tetany), hyperglycemia, glycosuria, elevated BUN, hyperuricemia. <span class="typehead">GI:</span> Nausea, vomiting, oral and gastric burning, anorexia, diarrhea, constipation, abdominal cramping, acute pancreatitis, jaundice. <span class="typehead">Urogenital:</span> Allergic interstitial nephritis, irreversible renal failure, urinary frequency. <span class="typehead">Hematologic:</span> Anemia, leukopenia, thrombocytopenic purpura; <span class="speceff-life">aplastic anemia, agranulocytosis</span> (rare). <span class="typehead">Special Senses:</span> Tinnitus, vertigo, feeling of fullness in ears, hearing loss (rarely permanent), blurred vision. <span class="typehead">Skin:</span> Pruritus, urticaria, exfoliative dermatitis, purpura, photosensitivity, porphyria cutanea tarde, necrotizing angiitis (vasculitis). <span class="typehead">Body as a Whole:</span> Increased perspiration; paresthesias; activation of SLE, muscle spasms, weakness; thrombophlebitis, pain at IM injection site. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Furosemide may cause elevations in <span class="alt">BUN,</span> <span class="alt">serum amylase,</span> <span class="alt">cholesterol,</span> <span class="alt">triglycerides,</span> <span class="alt">uric acid</span> and <span class="alt">blood glucose</span> levels, and may decrease <span class="alt">serum calcium,</span> <span class="alt">magnesium,</span> <span class="alt">potassium,</span> and <span class="alt">sodium</span> levels.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">other diuretics</span> enhance diuretic effects; with <b>digoxin</b> increased risk of toxicity because of hypokalemia; <span class="classification">nondepolarizing neuromuscular blocking agents</span> (e.g., <b>tubocurarine</b>) prolong neuromuscular blockage; <span class="classification">corticosteroids</span>, <b>amphotericin B</b> potentiate hypokalemia; decreased <b>lithium</b> elimination and increased toxicity; <span class="classification">sulfonylureas</span>, <b>insulin</b> blunt hypoglycemic effects; <span class="classification">nsaid</span>s may attenuate diuretic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 60 of oral dose absorbed from GI tract. <span class="typehead">Peak:</span> 6070 min PO; 2060 min IV. <span class="typehead">Onset:</span> 3060 min PO; 5 min IV. <span class="typehead">Duration:</span> 2 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead"> Metabolism:</span> Small amount metabolized in liver. <span class="typehead">Elimination:</span> Rapidly excreted in urine; 50% of oral dose and 80% of IV dose excreted within 24 h; excreted in breast milk. <span class="typehead">Half-Life:</span> 30 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe patients receiving parenteral drug carefully; closely monitor BP and vital signs. Sudden death from cardiac arrest
            has been reported.
         </li>
<li>Monitor for S&amp;S of hypokalemia (see Appendix F).</li>
<li>Monitor BP during periods of diuresis and through period of dosage adjustment.</li>
<li>Observe older adults closely during period of brisk diuresis. Sudden alteration in fluid and electrolyte balance may precipitate
            significant adverse reactions. Report symptoms to physician.
         </li>
<li>Lab tests: Obtain frequent blood count, serum and urine electrolytes, CO<sub>2</sub>, BUN, blood sugar, and uric acid values during first few months of therapy and periodically thereafter.
         </li>
<li>Monitor I&amp;O ratio and pattern. Report decrease or unusual increase in output. Excessive diuresis can result in dehydration
            and hypovolemia, circulatory collapse, and hypotension. Weigh patient daily under standard conditions.
         </li>
<li>Monitor urine and blood glucose &amp; HbA<sub>1C</sub> closely in diabetics and patients with decompensated hepatic cirrhosis. Drug may cause hyperglycemia.
         </li>
<li> 							Note: Excessive dehydration is most likely to occur in older adults, those with chronic cardiac disease on prolonged salt restriction,
            or those receiving sympatholytic agents. 						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Consult physician regarding allowable salt and fluid intake.</li>
<li>Ingest potassium-rich foods daily (e.g., bananas, oranges, peaches, dried dates) to reduce or prevent potassium depletion.</li>
<li>Learn S&amp;S of hypokalemia (see Appendix F). Report muscle cramps or weakness to physician.</li>
<li>Make position changes slowly because high doses of antihypertensive drugs taken concurrently may produce episodes of dizziness
            or imbalance.
         </li>
<li>Avoid replacing fluid losses with large amounts of water.</li>
<li>Avoid prolonged exposure to direct sun.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>